VBIV Stock Overview
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology.
VBI Vaccines Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.46|
|52 Week High||US$2.75|
|52 Week Low||US$0.45|
|1 Month Change||-27.75%|
|3 Month Change||-47.43%|
|1 Year Change||-82.24%|
|3 Year Change||-47.16%|
|5 Year Change||-88.01%|
|Change since IPO||-97.53%|
Recent News & Updates
Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?Jun 09
Is VBI Vaccines (NASDAQ:VBIV) Using Debt Sensibly?Jan 24
Is VBI Vaccines (NASDAQ:VBIV) Weighed On By Its Debt Load?Oct 06
VBI Vaccines (NASDAQ:VBIV) Has Debt But No Earnings; Should You Worry?Jul 08
The CEO Of VBI Vaccines Inc. (NASDAQ:VBIV) Might See A Pay Rise On The HorizonJun 03
Market Sentiment Around Loss-Making VBI Vaccines Inc. (NASDAQ:VBIV)Mar 30
The VBI Vaccines (NASDAQ:VBIV) Share Price Has Gained 178%, So Why Not Pay It Some Attention?Mar 02
Is VBI Vaccines Inc. (NASDAQ:VBIV) Popular Amongst Institutions?Feb 02
Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?Dec 29
How Much Is VBI Vaccines Inc. (NASDAQ:VBIV) Paying Its CEO?Dec 01
|VBIV||US Biotechs||US Market|
Return vs Industry: VBIV underperformed the US Biotechs industry which returned -6.5% over the past year.
Return vs Market: VBIV underperformed the US Market which returned -17.6% over the past year.
|VBIV Average Weekly Movement||8.6%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: VBIV is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: VBIV's weekly volatility (9%) has been stable over the past year.
About the Company
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.
VBI Vaccines Inc. Fundamentals Summary
|VBIV fundamental statistics|
Is VBIV overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VBIV income statement (TTM)|
|Cost of Revenue||US$11.21m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.43|
|Net Profit Margin||-12,752.30%|
How did VBIV perform over the long term?See historical performance and comparison